Table 1 Summary of participants enrolled in each year of the study and pre-vaccination levels of inflammatory mediators
Older adults | Young adults | ||
|---|---|---|---|
(N = 612) | (N = 79) | ||
Age | 76 (7.4) | 30 (4.9) | *** |
Sex | |||
Female | 410 (67.0%) | 58 (73.4%) | |
Male | 202 (33.0%) | 21 (26.6%) | |
BMI (kg/m2) | 28 (4.87) | 28 (7.25) | |
Missing | 3 (0.5%) | 10 (13%) | |
CMV serostatus | *** | ||
Negative | 287 (46.9%) | 62 (78.5%) | |
Positive | 325 (53.1%) | 17 (21.5%) | |
Frailty Index | 0.11 (0.073) | ||
Missing | 2 (0.3%) | ||
Dose | *** | ||
High-dose | 296 (48.4%) | 0 (0%) | |
Standard-dose | 316 (51.6%) | 79 (100%) | |
Site | |||
HSNRI | 356 (58.2%) | 40 (50.6%) | |
UCHC | 256 (41.8%) | 39 (49.4%) | |
Year | |||
2014/15 | 106 (17.3%) | 19 (24.1%) | |
2015/16 | 175 (28.6%) | 20 (25.3%) | |
2016/17 | 174 (28.4%) | 20 (25.3%) | |
2017/18 | 157 (25.7%) | 20 (25.3%) | |
TNF (pg/ml) | *** | ||
Mean (SD) | 12.1 (4.53) | 8.53 (1.62) | |
Median [Min, Max] | 11.1 [2.87, 43.8] | 8.45 [5.10, 12.7] | |
Missing | 3 (0.5%) | 1 (1%) | |
IL-6 (pg/ml) | *** | ||
Mean (SD) | 8.37 (43.0) | 1.60 (1.36) | |
Median [Min, Max] | 2.70 [0.464, 633] | 1.07 [0.193, 7.08] | |
Missing | 3 (0.5%) | 1 (1%) | |
CRP (mg/L) | |||
Low (< 5) | 429 (70.1%) | 54 (68.4%) | |
Medium (5–10) | 100 (16.3%) | 7 (8.9%) | |
High (10 +) | 41.0 (6.7%) | 9 (11.4%) | |
Missing | 42 (7%) | 9 (11%) | |